Immunotherapy for cancer in people living with HIV

Spano, Jean‐Philippe; Veyri, Marianne; Gobert, A.; Guihot, Amélie; Perre, Philippe Vande; Kerjouan, M.; Brosseau, Solenn; Cloarec, Nicolas; Montaudié, Henri; Hélissey, Carole; Flament, Thomas; Gounant, V.; Lavolé, A.; Poizot‐Martin, Isabelle; Katlama, Christine

doi:10.1097/qad.0000000000002298

Cited by 61 publications

(31 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For starting anti-PD-1/PD-L1 therapy, pretreatment CD4 + T cell counts should preferably be above 200 cells per mm 3 (level of evidence III, grade of recommendation B). 3 Patients with a CD4 + T cell counts below 100 cells per mm 3 have not been included in clinical trials of anti-PD-1/ PD-L1 antibodies. Therefore, while low CD4 + T cell counts are not an absolute contraindication to immunotherapy, careful evaluation of the risk to benefit ratio in these cases should be assessed (level of evidence V, grade of recommendation C) (figure 1).…”

Section: Hiv-1 Infection Incidence and Pathophysiologymentioning

confidence: 99%

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

González‐Cao

Puértolas²,

Riveiro³

et al. 2021

J Immunother Cancer

View full text Add to dashboard Cite

Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities.

show abstract

Section: Hiv-1 Infection Incidence and Pathophysiologymentioning

confidence: 99%

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

González‐Cao

Puértolas²,

Riveiro³

et al. 2021

J Immunother Cancer

View full text Add to dashboard Cite

show abstract

“…Before treatment with PD-1/PD-L1 inhibitors, a patient’s history of autoimmune disease and/or chronic viral infections should be taken into account. While it is uncommon, hepatitis B/C (HBV/HCV) and/or human immunodeficiency virus (HIV) can be exacerbated by immunotherapy [60, 61]. It is recommended that patients with underlying hepatitis or autoimmune disease be followed by a specialist in their field while receiving PD-1/PD-L1 inhibitors [60, 61].…”

Section: Introductionmentioning

confidence: 99%

Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway

Wakabayashi

Lee

Luh³

et al. 2019

J Biomed Sci

View full text Add to dashboard Cite

Dramatic advances in immune therapy have emerged as a promising strategy in cancer therapeutics. In addition to chemotherapy and radiotherapy, inhibitors targeting immune-checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) demonstrate impressive clinical benefits in clinical trials. In this review, we present background information about therapies involving PD-1/PD-L1 blockade and provide an overview of current clinical trials. Furthermore, we present recent advances involving predictive biomarkers associated with positive therapeutic outcomes in cancer immunotherapy.

show abstract

“…Confirmation in this sense came from another real-life experience from a series of PLWH cancer patients, of whom 21 were affected by NSCLC. The efficacy and safety of anti-PD1 agents nivolumab and pembrolizumab was demonstrated, and no negative effect of immunotherapy on T helper count and/or HIV-viral load was registered [82].…”

Section: Immunotherapymentioning

confidence: 99%

Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment

Frega

Ferro

Bonanno

et al. 2020

IJMS

View full text Add to dashboard Cite

The human immunodeficiency virus (HIV) infection continues to be a social and public health problem. Thanks to more and more effective antiretroviral therapy (ART), nowadays HIV-positive patients live longer, thus increasing their probability to acquire other diseases, malignancies primarily. Senescence along with immune-system impairment, HIV-related habits and other oncogenic virus co-infections increase the cancer risk of people living with HIV (PLWH); in the next future non-AIDS-defining cancers will prevail, lung cancer (LC) in particular. Tumor in PLWH might own peculiar predictive and/or prognostic features, and antineoplastic agents’ activity might be subverted by drug-drug interactions (DDIs) due to concurrent ART. Moreover, PLWH immune properties and comorbidities might influence both the response and tolerability of oncologic treatments. The therapeutic algorithm of LC, rapidly and continuously changed in the last years, should be fitted in the context of a special patient population like PLWH. This is quite challenging, also because HIV-positive patients have been often excluded from participation to clinical trials, so that levels of evidence about systemic treatments are lower than evidence in HIV-uninfected individuals. With this review, we depicted the epidemiology, pathogenesis, clinical-pathological characteristics and implications for LC care in PLWH, offering a valid focus about this topic to clinicians.

show abstract

Immunotherapy for cancer in people living with HIV

Cited by 61 publications

References 36 publications

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway

Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment

Contact Info

Product

Resources

About